May 19 2012
BIT Companies (www.BIT-Companies.com),
developer/manufacturer of in-vitro diagnostic, clinical and hematology
instrumentation, has announced its role as a supporter of Rays of
Hope, a non-profit organization in South Africa which offers
sustainable aid to underprivileged children in a small village on the
outskirts of Johannesburg, South Africa.
"Rays of Hope is funded purely by donations from private
individuals and involved companies such as BIT," explains Marius Balger,
CEO of BIT Companies. "The organization strives to provide a more stable
life to some of South Africa's township children - particularly to
children in dire need. Rays of Hope secures not only the survival
of these children; it prepares them to live a healthy and productive
life outside the township. We feel that it is important for business
corporations to be socially conscious and to help the less fortunate.
So, since the beginning of 2012, we have joined others in supporting
this worthy cause."
According to the Rays of Hope organization, its main objectives
are "to make our Village of Joy a place where violence as well as
alcohol- and drug-related abuse are replaced by devoted care and a ray
of hope on the horizon which makes every day worth living. Originally
founded by Milly Jarvis, a South African woman who has dedicated her
life to the cause, Rays of Hope has reached out to organizations
such as the Help Alliance from Lufthansa and BIT Companies,
both leading, international companies that respect their social
responsibility in a global world."
For over 35 years BIT Companies (http://www.BIT-companies.com)
have provided services in the field of contract development and
manufacturing as well as after-sales service for customers in the fields
of medical, diagnostics, life science, and biotechnology. As a part of
the financially strong Messer Group, BIT Companies provide their systems
solutions worldwide and in compliance with ISO 13485 and 9001 standards.
As registered contract service providers to the FDA, BIT Companies meet
the stringent regulations with regard to medical and complex medical
technical products while simultaneously adhering to predefined
design-to-cost and time-to-market targets.